Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 600 iu/ml - injection, solution - excipient ingredients: methionine; phosphoric acid; dibasic sodium phosphate dihydrate; water for injections; sucrose; poloxamer; sodium hydroxide; metacresol; monobasic sodium phosphate monohydrate - the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies. gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - corifollitropin alfa, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium hydroxide; sucrose; polysorbate 20; water for injections; methionine; hydrochloric acid - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - corifollitropin alfa, quantity: 0.3 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; sucrose; hydrochloric acid; polysorbate 20; water for injections; sodium hydroxide; methionine - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 625 iu/ml; lutropin alfa, quantity: 312.5 iu/ml - injection, solution - excipient ingredients: sucrose; poloxamer; methionine; phenol; arginine hydrochloride; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; phosphoric acid; water for injections - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 625 iu/ml; lutropin alfa, quantity: 312.5 iu/ml - injection, solution - excipient ingredients: sucrose; poloxamer; methionine; phenol; arginine hydrochloride; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; phosphoric acid; water for injections - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 625 iu/ml; lutropin alfa, quantity: 312.5 iu/ml - injection, solution - excipient ingredients: sucrose; poloxamer; methionine; phenol; arginine hydrochloride; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; phosphoric acid; water for injections - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - follitropin alfa, quantity: 300 iu - injection, solution - excipient ingredients: polysorbate 20; water for injections; sodium hydroxide; benzalkonium chloride; benzyl alcohol; mannitol; methionine; monobasic sodium phosphate dihydrate - 1. the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated.,2. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies.,3. ovaleap is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - follitropin alfa, quantity: 900 iu - injection, solution - excipient ingredients: polysorbate 20; benzalkonium chloride; sodium hydroxide; water for injections; benzyl alcohol; mannitol; methionine; monobasic sodium phosphate dihydrate - 1. the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated.,2. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies.,3. ovaleap is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - follitropin alfa, quantity: 450 iu - injection, solution - excipient ingredients: benzalkonium chloride; benzyl alcohol; mannitol; water for injections; methionine; polysorbate 20; sodium hydroxide; monobasic sodium phosphate dihydrate - 1. the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated.,2. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies.,3. ovaleap is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

gedeon richter australia pty ltd - follitropin alfa, quantity: 450 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- afolia is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- afolia in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- afolia is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.